Search Results - Daniel E. Furst

Refine Results
  1. 1
    The rational use of methotrexate in rheumatoid arthritis and other rheumatic diseases

    The rational use of methotrexate in rheumatoid arthritis and other rheumatic diseases by Daniel E. Fürst

    Published 1997
    Get full text Get full text
    Revisão
    Save to List
    Saved in:
  2. 2
    Updated consensus statement on biological agents for the treatment of rheumatoid arthritis and other immune mediated inflammatory diseases (May 2003)

    Updated consensus statement on biological agents for the treatment of rheumatoid arthritis and other immune mediated inflammatory diseases (May 2003) by Daniel E. Furst

    Published 2003
    Get full text Get full text
    Revisão
    Save to List
    Saved in:
  3. 3
    Updated consensus statement on biological agents, specifically tumour necrosis factor (TNF ) blocking agents and interleukin-1 receptor antagonist (IL-1ra), for the treatment of rheumatic diseases, 2005

    Updated consensus statement on biological agents, specifically tumour necrosis factor (TNF ) blocking agents and interleukin-1 receptor antagonist (IL-1ra), for the treatment of rh... by Daniel E. Furst

    Published 2005
    Get full text
    Revisão
    Save to List
    Saved in:
  4. 4
    Targeting inflammatory pathways in axial spondyloarthritis

    Targeting inflammatory pathways in axial spondyloarthritis by Daniel E. Furst, James S. Louie

    Published 2019
    Get full text Get full text
    Revisão
    Save to List
    Saved in:
  5. 5
    Biosimilars and the extrapolation of indications for inflammatory conditions

    Biosimilars and the extrapolation of indications for inflammatory conditions by John Tesser, Daniel E. Fürst, Ira Jacobs

    Published 2017
    Get full text Get full text
    Revisão
    Save to List
    Saved in:
  6. 6
    Salicylate Metabolism in Twins

    Salicylate Metabolism in Twins by Daniel E. Furst, Niroo Gupta, Harold E. Paulus

    Published 1977
    Get full text Get full text
    Artigo
    Save to List
    Saved in:
  7. 7
    Articular involvement in systemic sclerosis

    Articular involvement in systemic sclerosis by Jérôme Avouac, Philip J. Clements, Dinesh Khanna, Daniel E. Furst, Y. Allanore

    Published 2012
    Get full text
    Revisão
    Save to List
    Saved in:
  8. 8
    Systemic sclerosis trial design moving forward

    Systemic sclerosis trial design moving forward by Sindhu R. Johnson, Dinesh Khanna, Yannick Allanore, Marco Matucci‐Cerinic, Daniel E. Furst

    Published 2016
    Get full text
    Artigo
    Save to List
    Saved in:
  9. 9
    A Review of Recent Advances Using Tocilizumab in the Treatment of Rheumatic Diseases

    A Review of Recent Advances Using Tocilizumab in the Treatment of Rheumatic Diseases by Andrea Rubbert‐Roth, Daniel E. Furst, Jan Michael Nebesky, Angela Jin, Erhan Berber

    Published 2018
    Get full text Get full text
    Revisão
    Save to List
    Saved in:
  10. 10
    Longterm Safety of Rituximab: Final Report of the Rheumatoid Arthritis Global Clinical Trial Program over 11 Years

    Longterm Safety of Rituximab: Final Report of the Rheumatoid Arthritis Global Clinical Trial Program over 11 Years by Ronald van Vollenhoven, Roy Fleischmann, Daniel E. Fürst, Stuart R. Lacey, Patricia B. Lehane

    Published 2015
    Get full text Get full text
    Artigo
    Save to List
    Saved in:
  11. 11
    Points to consider for skin ulcers in systemic sclerosis

    Points to consider for skin ulcers in systemic sclerosis by Felice Galluccio, Yannick Allanore, L. Czirják, Daniel E. Furst, Dinesh Khanna, Marco Matucci‐Cerinic

    Published 2017
    Get full text Get full text
    Revisão
    Save to List
    Saved in:
  12. 12
    A Semiquantitative measure of cardiac involvement that improves prediction of prognosis in systemic sclerosis

    A Semiquantitative measure of cardiac involvement that improves prediction of prognosis in systemic sclerosis by Philip J. Clements, Peter A. Lachenbruch, Daniel E. Furst, Harold E. Paulus, Mildred G. Sterz

    Published 1991
    Get full text
    Artigo
    Save to List
    Saved in:
  13. 13
    GMP-Compliant Isolation and Large-Scale Expansion of Bone Marrow-Derived MSC

    GMP-Compliant Isolation and Large-Scale Expansion of Bone Marrow-Derived MSC by Natalie Fekete, Markus Rojewski, Daniel E. Furst, Ludwika Kreja, Anita Ignatius, Julia Dausend, Hubert Schrezenmeier

    Published 2012
    Get full text Get full text
    Artigo
    Save to List
    Saved in:
  14. 14
    Esophagitis in scleroderma

    Esophagitis in scleroderma by Barry J. Zamost, Joel Hirschberg, Andrew Ippoliti, Daniel E. Fürst, Phillip J. Clements, Wilfred M. Weinstein

    Published 1987
    Get full text
    Artigo
    Save to List
    Saved in:
  15. 15
    Assessment of skin involvement in systemic sclerosis

    Assessment of skin involvement in systemic sclerosis by Gabór Kumánovics, Márta Péntek, Sangmee Bae, Daniela Opriş-Belinski, Dinesh Khanna, Daniel E. Fürst, László Czirják

    Published 2017
    Get full text Get full text
    Revisão
    Save to List
    Saved in:
  16. 16
    POS0868 THE DEVELOPMENT OF THE LINEAR CRISS; A CLINICAL AND PATIENT MEANINGFUL ANCHOR TO THE ACR-CRISS IN SCLERODERMA.

    POS0868 THE DEVELOPMENT OF THE LINEAR CRISS; A CLINICAL AND PATIENT MEANINGFUL ANCHOR TO THE ACR-CRISS IN SCLERODERMA. by L. A. Bissell, Daniel E. Fürst, S. Johnson, Peter Hansen, E. Recalde, D. Khanna, F. Del Galdo

    Published 2022
    Get full text Get full text
    Artigo
    Save to List
    Saved in:
  17. 17
    Measurement of clinical change in progressive systemic sclerosis: a 1 year double-blind placebo-controlled trial of N-acetylcysteine.

    Measurement of clinical change in progressive systemic sclerosis: a 1 year double-blind placebo-controlled trial of N-acetylcysteine. by Daniel E. Fürst, Philip J. Clements, RP Harris, Michael G. Ross, Jason A. Levy, Harold E. Paulus

    Published 1979
    Get full text
    Artigo
    Save to List
    Saved in:
  18. 18
    POS0338 DEVELOPMENT AND VALIDATION OF RANKED COMPOSITE IMPORTANT DIFFERENCE (RCID) SCORE IN DIFFUSE CUTANEOUS SYSTEMIC SCLEROSIS

    POS0338 DEVELOPMENT AND VALIDATION OF RANKED COMPOSITE IMPORTANT DIFFERENCE (RCID) SCORE IN DIFFUSE CUTANEOUS SYSTEMIC SCLEROSIS by F. Del Galdo, L. A. Bissell, S. Huang, Peter Hansen, Sindhu R. Johnson, Daniel E. Furst, D. Khanna

    Published 2023
    Get full text Get full text
    Artigo
    Save to List
    Saved in:
  19. 19
    Microchimerism of maternal origin persists into adult life

    Microchimerism of maternal origin persists into adult life by Sean Maloney, Anajane G. Smith, Daniel E. Fürst, David Myerson, Kate Rupert, Paul C. Evans, J. Lee Nelson

    Published 1999
    Get full text Get full text
    Artigo
    Save to List
    Saved in:
  20. 20
    Vitamin D, Parathyroid Hormone, and Acroosteolysis in Systemic Sclerosis

    Vitamin D, Parathyroid Hormone, and Acroosteolysis in Systemic Sclerosis by Yolanda Braun‐Moscovici, Daniel E. Furst, Doron Markovits, Alexander Rozin, Philip J. Clements, Abraham Menahem Nahir, Alexandra Balbir‐Gurman

    Published 2008
    Get full text Get full text
    Artigo
    Save to List
    Saved in:

Search Tools: